Acetazolamide may prevent some patients with chronic obstructive pulmonary disease (COPD) from suffering altitude-related adverse health effects (ARAHE) when traveling, a randomized controlled trial showed.
In patients with moderate to severe COPD traveling to and staying for 2 days at 3,100 m, ARAHE occurred in 50% of those taking acetazolamide compared with 74% of those taking placebo (HR 0.60, 95% CI 0.40-0.89, P
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/ers/106326